India, March 15 -- AbbVie (ABBV) announced that final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE or mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha (FRa)-positive platinum-resistant ovarian cancer (PROC).
The Phase 3 MIRASOL study included 453 patients with high-grade serous epithelial platinum-resistant ovarian cancer or PROC whose tumors express high levels of FRa and had been treated with up to three prior therapies. Key findings from the 30.5-month median follow-up include: ELAHERE treatment achieved superior efficacy versus IC chemotherapy, with a median PFS of 5.59 months versus 3.98 months, representing a 37% red...